Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H19N3O5S |
| Molecular Weight | 461.49 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(C(=O)NC2=NC=CC=C2)=C(OC(=O)\C=C\C3=CC=CC=C3)C4=C(C=CC=C4)S1(=O)=O
InChI
InChIKey=GPUVGQIASQNZET-CCEZHUSRSA-N
InChI=1S/C24H19N3O5S/c1-27-22(24(29)26-20-13-7-8-16-25-20)23(18-11-5-6-12-19(18)33(27,30)31)32-21(28)15-14-17-9-3-2-4-10-17/h2-16H,1H3,(H,25,26,29)/b15-14+
| Molecular Formula | C24H19N3O5S |
| Molecular Weight | 461.49 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Piroxicam cinnamate (Cinnoxicam) is the anti-inflammatory agent. It is a cyclooxygenase inhibitor. Cinnoxicam was used in patients with inflammatory-degenerative osteoarticular diseases. The treatment brought about a significant improvement in the clinical variables considered (spontaneous pain at rest and on movement and functional limitation), which was observed within a few days of starting therapy. Tolerance was good, only a few slight side-effects having been reported. Cinnoxicam is a safe and reliable therapeutic option for men with oligoasthenospermia associated with a grade III varicocele, but surgery is better for those with grade II, IV and V. Piroxicam cinnamate as a long-acting prodrug is marketed by SPA in Italy for the treatment of rheumatic disorders.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Reduction in sperm aneuploidy levels in severe oligoasthenoteratospermic patients after medical therapy: a preliminary report. | 2012-07 |
|
| Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex. | 2007-08 |
|
| Male idiopathic oligoasthenoteratozoospermia. | 2006-03 |
|
| Cinnoxicam and L-carnitine/acetyl-L-carnitine treatment for idiopathic and varicocele-associated oligoasthenospermia. | 2004-08-05 |
|
| Medical therapy of oligoasthenospermia associated with left varicocele. | 2003-04 |
|
| [In vitro effects of L-carnitine on the inhibition of sperm mobility induced by FANS]. | 2000-08-25 |
|
| Stability study of piroxicam and cinnoxicam in solid pharmaceuticals. | 1999-06 |
|
| [Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial]. | 1996-04 |
|
| [Clinical evaluation of cinnoxicam 30 mg in patients with osteoarthrosis. A double-blind controlled study]. | 1996-03 |
|
| Contact allergy to cinnoxicam. | 1995-01 |
|
| Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. | 1994-02 |
|
| [Correlation of the lipophilicity of the active agents with their topical anti-inflammatory activity]. | 1992-07-01 |
|
| [Combined clinico-thermographic findings for the evaluation of a topical anti-inflammatory agent. Study of cinnoxicam cream]. | 1991-07-01 |
|
| [Evaluation of a new non-steroidal anti-inflammatory agent in degenerative osteo-articular pathology]. | 1991-06 |
|
| [Analgesic activity of cinnoxicam. Findings of clinical sensimetry]. | 1989-12-15 |
|
| [Clinical pharmacology of non-steroidal anti-inflammatory drugs. A new benzothiazine derivative: cinnoxicam]. | 1988-09 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:09:51 GMT 2025
by
admin
on
Mon Mar 31 18:09:51 GMT 2025
|
| Record UNII |
7E8Q32N75N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
87234-24-0
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
SUB14900MIG
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
33787
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID10236212
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
m8889
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | Merck Index | ||
|
W-149
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106889
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
C057291
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
C73032
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
655
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
7E8Q32N75N
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
100000079144
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY | |||
|
6436090
Created by
admin on Mon Mar 31 18:09:51 GMT 2025 , Edited by admin on Mon Mar 31 18:09:51 GMT 2025
|
PRIMARY |